Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:TARA

Protara Therapeutics Q3 2025 Earnings Report

Protara Therapeutics logo
$5.66 +0.25 (+4.62%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$5.62 -0.04 (-0.80%)
As of 05/6/2026 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Protara Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Protara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Protara Therapeutics Announcement Details

Quarter
Q3 2025
Date
11/10/2025
Time
Before Market Opens
Conference Call Date
Monday, November 10, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Protara Therapeutics' Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Protara Therapeutics' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Protara Therapeutics' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Protara Therapeutics Earnings Headlines

One Protara Therapeutics Insider Raised Their Stake In The Previous Year
May 4 at 8:39 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/one-protara-therapeutics-insider-raised-101508094.html
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-na-ve-nmibc-patients-at-the-american-urological-association-annual-meeting-1036068262
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel
 |  American Alternative (Ad)
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3282012/0/en/protara-therapeutics-to-present-updated-interim-12-month-data-from-the-phase-2-advanced-2-trial-of-tara-002-in-bcg-na%c3%afve-nmibc-patients-at-the-american-urological-association-annua.html
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
March 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/10/3252699/0/en/protara-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update.html
Protara reports encouraging phase 2 results for TARA-002 in bladder cancer study
February 25, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/protara-reports-encouraging-phase-2-results-for-tara-002-in-bladder-cancer-study/ar-AA1WYMTn
See More Protara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protara Therapeutics and other key companies, straight to your email.

About Protara Therapeutics

Protara Therapeutics (NASDAQ:TARA) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells. By engaging OX40, PTX-35 aims to amplify anti-tumor T-cell responses and promote durable immunity against viral antigens. The company has also advanced preclinical vaccine programs targeting high-grade cervical dysplasia driven by HPV-16 and HPV-18, with the goal of reducing the need for surgical intervention.

Headquartered in San Diego, California, Protara conducts early-stage clinical trials in North America and collaborates with academic research centers to explore combination regimens and next-generation immuno-oncology approaches. As a Nasdaq-listed company under the ticker TARA, Protara Therapeutics continues to build its pipeline through internal research and strategic partnerships aimed at addressing unmet needs in virus-associated oncology.

View Protara Therapeutics Profile
Earnings Tools